Enrollment complete in EyePoint phase 2 nonproliferative diabetic retinopathy trial
Click Here to Manage Email Alerts
Key takeaways:
- EYP-1901 combines sustained delivery technology and vorolanib.
- The study will assess improvement in diabetic retinopathy severity scale levels.
EyePoint Pharmaceuticals completed enrollment in the phase 2 PAVIA clinical trial to assess EYP-1901 for the treatment of moderate to severe nonproliferative diabetic retinopathy, according to a press release.
EYP-1901 is a sustained delivery treatment that includes an erodible formulation of EyePoint’s Durasert delivery technology and vorolanib, a tyrosine kinase inhibitor.
Image: Adobe Stock
PAVIA is a 12-month randomized controlled trial that comprises 77 participants with moderate to severe nonproliferative diabetic retinopathy receiving either 2 mg or 3 mg of EYP-1901 or sham injection. The primary efficacy endpoint is improvement of at least two diabetic retinopathy severity scale levels at week 36 after injection.
Secondary endpoints include reduction in vision-threatening complications, occurrence of diabetic macular edema and safety, the release said.
“Despite the risk for visual loss associated with this disease, over 90% of patients currently receive no course of treatment apart from observation by their eye care specialist until they develop sight-threatening complications,” Nancy Lurker, EyePoint CEO, said in the release. “This is due to the burdensome and frequent eye injections currently required with today’s approved therapies for this disease. As a result, we believe EYP-1901 may address the substantial therapeutic unmet need for a long-acting treatment.”
Read more about
Click Here to Manage Email Alerts